Loading patent…
AssigneeAllergan, Inc.
InventorsEldon Quinn Farnes, Mayssa Attar, Rhett M. Schiffman, Ching-Ming Chang, Richard S. Graham, Devin F. Welty
Estimating the term…
The present invention provides an aqueous ophthalmic solution comprising an effective amount of ketorolac which comprises carboxymethyl cellulose in an aqueous solution wherein said concentration of carboxymethyl cellulose is selected to provide an increased absorption of ketorolac in the eye of a patient that is at least 130% greater than the absorption of a comparative aqueous ketorolac ophthalmic solution having the same concentration of ketorolac.
A first composition for treating ocular pain and inflammation following cataract surgery comprising about 0.45% w/v ketorolac and about 0.5% w/v carboxymethyl cellulose.
A first composition for treating ocular pain and inflammation comprising about 0.45% w/v ketorolac and about 0.5% w/v carboxymethyl cellulose, wherein the twice daily topical administration of the first composition to the eye increases bioavailability of ketorolac in the eye relative to the twice daily topical administration of a second composition comprising about 0.4% w/v ketorolac and no carboxymethyl cellulose.
A first composition for treating ocular pain and inflammation comprising 0.45% w/v ketorolac tromethamine and 0.5% w/v carboxymethyl cellulose, wherein the twice daily topical administration of the first composition to an eye increases the bioavailability of the ketorolac in the eye relative to the four times daily topical administration of a second composition to an eye comprising about 0.4% ketorolac tromethamine and no carboxymethyl cellulose.
A composition for treating ocular pain and inflammation comprising 0.45% w/v ketorolac tromethamine, 0.5% w/v carboxy methyl cellulose, 0.7% w/v sodium chloride, 0.2% sodium citrate dihydrate and water.
Dependencies are inferred from the claim text.